Immune recall enhances cross-reactive antibody longevity after a large wave of SARS-CoV-2 breakthrough infection

Dan Li; Qingfei Chu; Kang Li; Lanjuan Li; Yiming Shao

doi:10.1038/s41392-024-01926-w

Immune recall enhances cross-reactive antibody longevity after a large wave of SARS-CoV-2 breakthrough infection

Signal Transduct Target Ther. 2024 Aug 21;9(1):208. doi: 10.1038/s41392-024-01926-w.

Authors

Dan Li^#^{1

2}, Qingfei Chu^#^{1

2}, Kang Li^#², Lanjuan Li³, Yiming Shao^{4

5}

Affiliations

¹ State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China.
² National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China.
³ State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China. [email protected].
⁴ State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China. [email protected].
⁵ National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China. [email protected].

^# Contributed equally.

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Viral* / immunology
Breakthrough Infections* / immunology
Breakthrough Infections* / virology
COVID-19* / immunology
COVID-19* / virology
Cross Reactions* / immunology
Female
Humans
Immunologic Memory
Male
SARS-CoV-2* / immunology

Substances

Antibodies, Viral

Grants and funding

U20A20362/National Natural Science Foundation of China (National Science Foundation of China)